{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T18:43:25Z","timestamp":1772909005595,"version":"3.50.1"},"reference-count":31,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jhltonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Heart and Lung Transplantation"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.healun.2022.01.010","type":"journal-article","created":{"date-parts":[[2022,1,15]],"date-time":"2022-01-15T02:47:12Z","timestamp":1642214832000},"page":"538-549","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Clinical outcomes of heart transplantation using hepatitis c-viremic donors: A systematic review with meta-analysis"],"prefix":"10.1016","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5803-3188","authenticated-orcid":false,"given":"Josue","family":"Villegas-Galaviz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0109-6350","authenticated-orcid":false,"given":"Eve","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maya","family":"Guglin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.healun.2022.01.010_bib0001","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1111\/ajt.14381","article-title":"The American Society of Transplantation Consensus Conference on the use of hepatitis C viremic donors in solid organ transplantation","volume":"17","author":"Levitsky","year":"2017","journal-title":"Am J Transplant"},{"key":"10.1016\/j.healun.2022.01.010_bib0002","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/j.healun.2019.08.010","article-title":"The impact of using hepatitis C virus nucleic acid test-positive donor hearts on heart transplant waitlist time and transplant rate","volume":"38","author":"Gernhofer","year":"2019","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.healun.2022.01.010_bib0003","doi-asserted-by":"crossref","first-page":"S132","DOI":"10.1016\/j.healun.2019.01.313","article-title":"Cost effectiveness of using hepatitis C Virus (HCV)-viremic hearts for transplantation into HCV-negative recipients","volume":"38","author":"Logan","year":"2019","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.healun.2022.01.010_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/S0016-5085(20)33980-9","article-title":"Implementation of HCV+ donor heart protocol produces net overall cost savings in cardiac transplantation","volume":"158","author":"Wang","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.healun.2022.01.010_bib0005","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1001\/jama.296.15.1843","article-title":"Hepatitis C virus seropositivity in organ donors and survival in heart transplant recipients","volume":"296","author":"Gasink","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.healun.2022.01.010_bib0006","doi-asserted-by":"crossref","first-page":"P2492","DOI":"10.1053\/j.jvca.2019.12.012","article-title":"High-risk and hepatitis C-Positive organ donors: current practice in heart, lung, and liver transplantation","volume":"34","author":"Chacon","year":"2019","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"10.1016\/j.healun.2022.01.010_bib0007","doi-asserted-by":"crossref","first-page":"637","DOI":"10.7326\/M16-2575","article-title":"Oral direct-acting agent therapy for hepatitis C virus infection: a systematic review","volume":"166","author":"Falade-Nwulia","year":"2017","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.healun.2022.01.010_bib0008","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1002\/hep.31060","article-title":"Panel A-IHCG. Hepatitis C Guidance 2019 update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America recommendations for testing, managing, and treating hepatitis C virus infection","volume":"71","author":"Ghany","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.healun.2022.01.010_bib0009","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/S2468-1253(19)30240-7","article-title":"Pre-emptive pangenotypic direct acting antiviral therapy in donor HCV-positive to recipient HCV-negative heart transplantation: an open-label study","volume":"4","author":"Bethea","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.healun.2022.01.010_bib0010","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S2468-1253(20)30081-9","article-title":"Short-course, direct-acting antivirals and ezetimibe to prevent HCV infection in recipients of organs from HCV-infected donors: a phase 3, single-centre, open-label study","volume":"5","author":"Feld","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.healun.2022.01.010_bib0011","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1056\/NEJMoa1812406","article-title":"Heart and lung transplants from HCV infected donors to uninfected recipients","volume":"380","author":"Woolley","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.healun.2022.01.010_bib0012","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/CRD.0000000000000255","article-title":"Heart transplantation for hepatitis C virus non-viremic recipients from hepatitis C virus viremic donors","volume":"27","author":"Frager","year":"2019","journal-title":"Cardiol Rev"},{"key":"10.1016\/j.healun.2022.01.010_bib0013","doi-asserted-by":"crossref","first-page":"e13764","DOI":"10.1111\/ctr.13764","article-title":"Hepatitis C donor viremic cardiac transplantation: a practical approach","volume":"34","author":"Morris","year":"2020","journal-title":"Clin Transplant"},{"key":"10.1016\/j.healun.2022.01.010_bib0014","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1111\/ajt.15311","article-title":"Transplanting hepatitis C virus-infected hearts into uninfected recipients: a single-arm trial","volume":"19","author":"McLean","year":"2019","journal-title":"Am J Transplant"},{"key":"10.1016\/j.healun.2022.01.010_bib0015","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1001\/jamacardio.2019.4748","article-title":"Expanding heart transplant in the era of direct-acting antiviral therapy for hepatitis C","volume":"5","author":"Schlendorf","year":"2019","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.healun.2022.01.010_bib0016","doi-asserted-by":"crossref","first-page":"e13989","DOI":"10.1111\/ctr.13989","article-title":"Outcomes of the treatment with glecaprevir\/pibrentasvir following heart transplantation utilizing hepatitis C viremic donors","volume":"34","author":"Reyentovich","year":"2020","journal-title":"Clin Transplant"},{"key":"10.1016\/j.healun.2022.01.010_bib0017","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/j.healun.2019.08.019","article-title":"Outcomes of heart transplantation from hepatitis C virus\u2013positive donors","volume":"38","author":"Aslam","year":"2019","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.healun.2022.01.010_bib0018","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.transproceed.2019.01.025","article-title":"Heart transplantation in systemic sclerosis: new impulses for conventional scleroderma transplantation regimen and scleroderma diagnostic monitoring: 2 case reports","volume":"51","author":"Faust","year":"2019","journal-title":"Transplant Proc"},{"key":"10.1016\/j.healun.2022.01.010_bib0019","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.cardfail.2017.08.448","article-title":"Rational heart transplant from a hepatitis C donor: new antiviral weapons conquer the trojan horse","volume":"23","author":"Gottlieb","year":"2017","journal-title":"J Card Fail"},{"key":"10.1016\/j.healun.2022.01.010_bib0020","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/hep.31011","article-title":"Hepatitis C virus NAT-positive solid organ allografts transplanted into hepatitis C virus\u2013negative recipients: a real-world experience","volume":"72","author":"Kapila","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.healun.2022.01.010_bib0021","doi-asserted-by":"crossref","first-page":"e13308","DOI":"10.1111\/ctr.13308","article-title":"Accepting hepatitis C virus-infected donor hearts for transplantation: Multistep consent, unrealized opportunity, and the Stanford experience","volume":"32","author":"Moayedi","year":"2018","journal-title":"Clin Transplant"},{"key":"10.1016\/j.healun.2022.01.010_bib0022","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"10.1016\/j.healun.2022.01.010_bib0023","doi-asserted-by":"crossref","first-page":"P418","DOI":"10.1016\/j.healun.2020.03.004","article-title":"Utilization of hepatitis C virus-infected organ donors in cardiothoracic transplantation: an ISHLT expert consensus statement","volume":"39","author":"Aslam","year":"2020","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.healun.2022.01.010_bib0024","first-page":"154","article-title":"Concordance of sustained virologic response at weeks 4, 12 and 24 post-treatment of hepatitis c in the era of new oral direct-acting antivirals: a concise review","volume":"15","author":"Burgess","year":"2016","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.healun.2022.01.010_bib0025","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1034\/j.1600-6143.2002.20508.x","article-title":"Hepatitis C-positive donors in heart transplantation","volume":"2","author":"Marelli","year":"2002","journal-title":"Am J Transplant"},{"key":"10.1016\/j.healun.2022.01.010_bib0026","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/S1053-2498(00)00062-0","article-title":"Hepatitis C transmission and infection by orthotopic heart transplantation","volume":"19","author":"Pfau","year":"2000","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.healun.2022.01.010_bib0027","doi-asserted-by":"crossref","first-page":"e486","DOI":"10.1097\/TXD.0000000000000928","article-title":"Heart transplantation from hepatitis C-positive donors in the era of direct acting antiviral therapy: a comprehensive literature review","volume":"5","author":"Bruno","year":"2019","journal-title":"Transplant Direct"},{"issue":"s1","key":"10.1016\/j.healun.2022.01.010_bib0028","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/ajt.15676","article-title":"OPTN\/SRTR 2018 annual data report: heart","volume":"20","author":"Colvin","year":"2020","journal-title":"Am J Transplant"},{"key":"10.1016\/j.healun.2022.01.010_bib0029","doi-asserted-by":"crossref","first-page":"e014495","DOI":"10.1161\/JAHA.119.014495","article-title":"Outcomes of adult heart transplantation using hepatitis C\u2013positive donors","volume":"9","author":"Kilic","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.healun.2022.01.010_bib0030","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.118.005276","article-title":"Current use of hearts from hepatitis C viremic donors","volume":"11","author":"Moayedi","year":"2018","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.healun.2022.01.010_bib0031","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1111\/ajt.15857","article-title":"Local and regional variability in utilization and allocation of hepatitis C virus-infected hearts for transplantation","volume":"20","author":"Prakash","year":"2020","journal-title":"Am J Transplant"}],"container-title":["The Journal of Heart and Lung Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053249822000158?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053249822000158?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T08:43:26Z","timestamp":1760949806000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1053249822000158"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["S1053249822000158"],"URL":"https:\/\/doi.org\/10.1016\/j.healun.2022.01.010","relation":{},"ISSN":["1053-2498"],"issn-type":[{"value":"1053-2498","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical outcomes of heart transplantation using hepatitis c-viremic donors: A systematic review with meta-analysis","name":"articletitle","label":"Article Title"},{"value":"The Journal of Heart and Lung Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.healun.2022.01.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 International Society for Heart and Lung Transplantation. All rights reserved.","name":"copyright","label":"Copyright"}]}}